Navigating ESG challenges in pharma and logistics: the road to sustainability

Published: 18-Mar-2025
Distribution Sustainability Pharmaceutical

Jake Brown, Commercial Lead at LogiPharma, discusses the upcoming 25th edition of the conference and how some of its key sponsors are navigating ESG challenges

You need to be a subscriber to read this article.
Click here to find out more.

As the world pivots towards a more sustainable future, industries across the board are facing increasing pressure to reduce their environmental impact and improve their social and governance (ESG) practices.

This shift is particularly evident in the pharma and logistics sectors where sustainability is becoming a core tenet of business strategy … with a significant emphasis on mitigating climate change.

The upcoming 25th edition of the LogiPharma conference will bring to light how global pharmaceutical companies and logistics giants are tackling these challenges head-on.


Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • DHL Group
  • Worldwide Business Research
  • DSV Road Ltd
See more

You may also like

Distribution

DHL acquires specialty CGT and biopharma courier, CRYOPDP

Read more
The biopharmaceutical and cell& gene therapy courier currently ships to 15 countries, and will expand DHL's global specialised pharmaceutical footprint

Trending Articles

  1. Roche to put $50bn into US manufacturing and R&D footprint The company will build new gene therapy, weight loss medication and continuous glucose monitoring manufacturing facilities situated across the US, as well as dedicated R&D centres
  2. Jazz Pharmaceuticals commercialises enhanced antibody, Ziihera, for biliary tract cancer The therapeutic antibody was developed using ProBioGen's GlyMaxX technology, creating an afucosylated product with more ADCC-mediated cell killing activity
  3. Cut Argon use and costs with Shimadzu’s ICPMS-2040/2050 New Mini-Torch System offers precision analysis with 40% less Argon
  4. Generic drugmakers in Asia focus more on market expansion and quality and less on patent cliff, finds report India has emerged as a major market for the consumption and manufacture of generic medicines, says Frost & Sullivan
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Autoinjector development The autoinjector is one of the fastest emerging drug delivery solutions. It consists of a pre-filled syringe or cartridge inside a device that applies enough force to inject fully the desired drug within the specified requirements. Insufficient planning and early conceptual design vulnerabilities can result in quality issues, prolonged project timeline and increased cost. A device manufacturing partner will therefore need basic mechanical device knowledge and regulatory experience.

Upcoming event

Boosting Sustainability and Efficiency in Pharma Manufacturing

14 May 2025 | Virtual See all

You may also like

Distribution

DHL acquires specialty CGT and biopharma courier, CRYOPDP

The biopharmaceutical and cell& gene therapy courier currently ships to 15 countries, and will expand DHL's global specialised pharmaceutical footprint
Distribution

The long road to pharmaceutical sustainability

A new sustainability report commissioned by LogiPharma has revealed that whereas most pharmaceutical businesses are on the right path, 85% currently consider themselves to be only “somewhat sustainable”
Pharmaceutical

Multimodal aims to become key event for pharmaceutical industry

The supply chain is a very important component of the pharmaceutical industry, says organiser
Pharmaceutical

How microsphere drug delivery systems work

Microsphere drug delivery systems are changing how medicine is administered, enhancing drug effectiveness, minimising side effects, and improving patient outcomes. These advancements are pivotal in treatments ranging from cancer therapies to next-generation vaccines, enabling precise, sustained, and targeted drug delivery. But what makes this technology so innovative, and how does it work?
Pharmaceutical

Jazz Pharmaceuticals commercialises enhanced antibody, Ziihera, for biliary tract cancer

The therapeutic antibody was developed using ProBioGen's GlyMaxX technology, creating an afucosylated product with more ADCC-mediated cell killing activity
Sustainability

Cut Argon use and costs with Shimadzu’s ICPMS-2040/2050

New Mini-Torch System offers precision analysis with 40% less Argon
Research & Development

Roche to put $50bn into US manufacturing and R&D footprint

The company will build new gene therapy, weight loss medication and continuous glucose monitoring manufacturing facilities situated across the US, as well as dedicated R&D centres
Subscribe now